Drug intelligence / Profile preview

MAG-SPM

Development stage: Preclinical
Lead developer: SCF Pharma
Administration: Oral

Overview

MAG-SPM is an experimental formulation consisting of monoglyceride omega-3 fatty acids that are pre-metabolized to produce specialized pro-resolving mediators (SPMs) using a lipoxygenase enzyme from soy. SPMs are bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (PUFAs), with a primary function in promoting the resolution of inflammation and restoration of tissue homeostasis. MAG-SPM is developed to enhance the anti-inflammatory and resolution properties of omega-3 supplements and is being studied for its effects on inflammation in vitro, specifically in human peripheral blood mononuclear cells (PBMCs). Its mechanism involves acting as a precursor/enhancer of SPMs that are naturally produced in the body by selective oxidation of omega-3s[2].

Beyond the preview

Go deeper on MAG-SPM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAG-SPM.

Explore the full profile